(b)

	Edema (% recipients)	Wound complications (% recipients)	Ulcers (% recipients)	Bile duct complications (% recipients)	Infections (% recipients)	Dermatological effects (% recipients)	Hematological effects (% recipients)
De novo dosing
Chinnakotla et al. Liver Transpl. 2009; 15: 1834–1842 [55]		Wound dehiscence: 3.31 versus 1.89 (SRL versus TAC, P = NS)
McKenna et al. Am J Transplant. 2011; 11: 2379–87 [57]					CMV: 13.3 versus 20.2 (SRL versus controls, P = 0.07)
Sanchez et al. Transplant Proc. 2005; 37 (10): 4416–23 [69]		Wound infection: 13.8 Wound dehiscence: 6.9 (both de novo)			Bacterial infection: 34.5 versus 22.9 CMV: 3.4 versus 14.3 (de novo versus conversion)		Leukopenia: 6.9 versus 25.7 (de novo versus conversion) Thrombocytopenia: 13.7 versus 8.6 (de novo versus conversion)
Molinari et al. Transpl Intl 2010; 23: 155–68 [53]		Wound complications: 15 versus 11.6 (SRL versus CNI, P = NS) Incisional hernias: 8.7 versus 7.2 (P = NS)		19.4 versus 18.5 (SRL versus CNI, P = NS)	Opportunistic infections: 18.5 versus 13 CMN: 2.6 versus 2.7 Herpes virus pneumonia: 0 versus 0.9 (SRL versus CNI, 6 months, P = NS for all)
Dunkelberg et al. Liver Transpl. 2003; 9: 463–8 [61]		Wound complications: 12.4 versus 13.9 (SRL versus controls, P = NS)
Zimmerman et al. Liver Transpl. 2008; 14: 633–8 [15]		Wound infection: 2.2 versus 3.8 (SRL versus CNI)
Early conversion (≤3 months after transplantation)
Rogers et al. Clin Transplant. 2009; 23: 887–96 [48]		Incisional hernia: 14 versus 15 (SRL versus CNI, P = NS) Poor wound healing: 6 versus 20 (P = 0.017)	Oral ulcers: 15 versus 3 (SRL versus CNI, P = 0.019)		CMV disease: 13 versus 6 (SRL versus CNI, P = NS)	Facial rash: 8 versus 5 (SRL versus CNI, P = NS)	Leukopenia: 20 versus 12 (SRL versus CNI, P = NS) Anemia: 44 versus 11 (SRL versus CNI, P < 0.001)
Harper et al. Transplantation. 2011; 91: 128–32 [67]	Peripheral edema: 21		Mouth ulcer: 15		Pneumonitis: 5	Rash: 7	Anemia: 11
Schleicher et al. Transplant Proc. 2010; 42: 2572–5 [49]		Incisional hernia: 7					Leukopenia: 12 Thrombocytopenia: 10.5 Anemia: 9
Late conversion (>3 months after transplantation)
Campbell et al. Clin Transplant. 2007; 21: 377–84 [71]	Leg edema: 5
DuBay et al. Liver Transpl. 2008; 14: 651–9 [72]	Lower extremity edema: 23 versus 11 (SRL versus CNI, P = 0.08)						Anemia: 16 versus 12 (SRL versus CNI, P = NS)
Watson et al. Liver Transpl. 2007; 13: 1694–702 [78]	Edema: 30.8 versus 7.1 (SRL versus CNI)	Slow wound healing: 7.7 versus 0 (SRL versus CNI)	Oral ulcers: 38			Rash: 69 versus 0 (SRL versus CNI)	Thrombocytopenia: 23 versus 14.3 (SRL versus CNI)
Herlenius et al. Transplant Proc. 2010; 42: 4441–8 [73]			Oral ulcers: 42 versus 0 (SRL versus MMF, P = 0.01)		Infectious episode: 33.3 versus 38.5 (SRL versus MMF, P = NS)
Morard et al. Liver Transpl. 2007; 13: 658–64 [75]	Ankle edema: 14		Oral ulcer: 12		Infection: 2	Dermatitis: 14
Shenoy et al. Transplantation. 2007; 83: 1389–92 [76]						Mouth sores: 25 versus 0 (SRL versus CNI) Pruritus: 5 versus 0 (SRL versus CNI)
Uhlmann et al. Exp Clin Transplant. 2012; 10: 30–8 [77]			Oral ulcer: 16
Fairbanks et al. Liver Transpl. 2003; 9: 1079–85 [83] (Low)			Oral ulcer: 9.5			Rash: 9.5 Acne: 9.5	Anemia: 23.8 Leukopenia: 9.5 Thrombocytopenia: 14.3
Di Benedetto et al. Transplant Proc. 2009; 41: 1297–9 [81]							Thrombocytopenia (leading to withdrawal): 12.9
Abdelmalek et al. Am J Transplant. 2012; 12: 694–705 [45]	Peripheral edema: 33 versus 14 (SRL versus CNI, P < 0.001)		Oral ulcer: 11 versus 1 (SRL versus CNI, P < 0.001)		Herpes simpex: 9 versus 1 (SRL versus CNI, P < 0.001) Hepatitis: 2 versus 0 (SRL versus CNI, P = 0.03)	29 versus 8 (SRL versus CNI, P < 0.001)
Vivarelli et al. Transplant Proc. 2010; 42: 2579–84 [80]	Lower limb edema: 23.3		Oral ulcer: 5.8			Rash: 5.8	Anemia: 13.9

P values are included where available.

CMV: cytomegalovirus; CNI: calcineurin inhibitor; MMF: mycophenolate mofetil; NS: non-significant; SRL: sirolimus; TAC: tacrolimus.